Annovis Secures Buntanetap Patent Ahead of Alzheimer’s Trial Data

Annovis Bio

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has secured U.S. patent protection through June 2044 for the formulation of its experimental Alzheimer’s and Parkinson’s treatment buntanetap, strengthening its intellectual property position ahead of pivotal clinical trial results expected in early 2027.

The U.S. Patent and Trademark Office issued Patent No. 12,780,831 on November 3, covering a crystalline form of buntanetap known as Form B, which Annovis is using in its ongoing clinical development programs.

The patent contains 11 claims covering the drug’s crystalline structure, pharmaceutical compositions and manufacturing methods. Protection extends through June 21, 2044.

The patent comes as Annovis approaches a significant clinical milestone for buntanetap, an investigational once-daily oral treatment being evaluated for neurodegenerative diseases.

The company has completed enrollment in its pivotal Phase 3 trial involving patients with early Alzheimer’s disease who test positive for the blood biomarker pTau217.

READ:  Teleflex Sets 34-Cent Quarterly Dividend for December

The study is evaluating a 30-milligram daily dose of buntanetap and includes two planned assessments: a six-month analysis of symptomatic effects and an 18-month analysis of potential disease-modifying effects.

Annovis expects initial results from the symptomatic analysis in the first quarter of 2027, followed by disease-modifying results in the first quarter of 2028.

The company has begun preparing New Drug Application submissions to the Food and Drug Administration following the respective trial readouts.

“Securing composition of matter protection for the new crystal form of buntanetap is an important milestone for Annovis,” said Maria Maccecchini, the company’s founder, president and chief executive officer.

READ:  Teleflex Raises Earnings Outlook as Profit Rebounds

“This patent covers the form of buntanetap (Form B) that we have moved into our clinical program, and it strengthens our position as we approach the readout of our pivotal Phase 3 Alzheimer’s study and prepare for regulatory submissions that will follow.”

Form B is also being used in an open-label extension study involving patients with Parkinson’s disease.

The patented formulation differs structurally from the earlier Form A version of buntanetap. Form B is a crystalline dihydrate, while Form A is a semi-crystalline anhydrate.

According to Annovis, Form B demonstrated stability during laboratory testing, maintaining its crystalline structure after vacuum drying and milling. The company reported purity of 99.9% using high-performance liquid chromatography.

Comparative pharmacokinetic studies in mice, dogs and humans found similar drug exposure profiles between the two formulations in plasma, brain tissue and cerebrospinal fluid.

READ:  West Pharmaceutical to Address Investors at London Conference

Those findings were submitted to the FDA and published in the peer-reviewed journal Biomolecules.

Annovis initially filed its patent application for the new solid forms in June 2024. The FDA cleared the company’s transition to Form B for future clinical trials in July 2024 after reviewing comparative studies and manufacturing data.

The new patent protects the specific crystalline formulation used in Annovis’ clinical programs as the company moves toward its first pivotal Alzheimer’s trial results.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.